The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

July 25, 2018

What the Next Generation of Cancer Biomarkers May Involve

Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.

January 30, 2014

Selecting the Appropriate Test for Individual Patients and Tumors

In this next segment, Dr Agarwala discusses when and how molecular tests should be utilized.